

1 ALLEN RUBY, SB #47109
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
2 525 University Avenue, Suite 1100
Palo Alto, CA 94301
3 Telephone:650-470-4500
Facsimile: 650-470-4570

4 CRISTINA C. ARGUEDAS, SB #87787
5 TED W. CASSMAN, SB #98932
ARGUEDAS, CASSMAN & HEADLEY
6 803 Hearst Avenue
Berkeley, CA 94710
7 Telephone: 510-845-3000
Facsimile: 510-845-3003

8 DENNIS P. RIORDAN, SB # 69320
9 DONALD M. HORGAN, SB #121547
RIORDAN & HORGAN
10 523 Octavia Street
San Francisco, CA 94102
11 Telephone: 415-431-3472
Facsimile: 415-552-2703

12
13 Attorneys for Defendant
BARRY BONDS
14

15 UNITED STATES DISTRICT COURT
16 NORTHERN DISTRICT OF CALIFORNIA
17 SAN FRANCISCO DIVISION
18

19 UNITED STATES OF AMERICA,) Case No.: CR 07-0732 SI
20 Plaintiffs,) EXHIBIT "A" TO
21 vs.) MOTION IN LIMINE NO. 5
22 BARRY LAMAR BONDS,) MOTION OF DEFENDANT BARRY L.
23 Defendants) BONDS TO PROHIBIT EXPERT
24) OPINION TESTIMONY WHICH WAS
25) NOT DISCLOSED TO THE DEFENSE
26) PURSUANT TO RULE 16(a)(1)(G),
27) Federal Rules of Criminal Procedure
28)

Date: March 1, 2011
Hon: Susan Illston



United States Attorney
Northern District of California

150 Almaden Blvd.
Suite 900
San Jose, California 95113

(408) 535-5061
FAX: (408) 535-5066

January 20, 2009

Allen Ruby, Esq.
Law Offices of Allen Ruby
125 South Market Street, Suite 1001
San Jose, CA 95113

Re: United States v. Barry L. Bonds
CR 07-0732 SI

Dear Mr. Ruby:

In accordance with the Federal Rules of Criminal Procedure, Rule 16(a)(1)(G), the United States hereby provides notice of intent to introduce expert testimony at trial. It should be noted that the Grand Jury transcripts of both witnesses have previously been disclosed to the defense and that such disclosure is incorporated into this notice. The government will provide further information regarding any other expert witnesses as it becomes available.

Dr. Don H. Catlin

A. Qualifications

Dr. Catlin is a medical doctor who was employed as the Director of the UCLA Olympic Analytical Laboratory (UCLA Olympic Lab) during the relevant time period to this indictment. A copy of Dr. Catlin's curriculum vitae, which details his qualifications to offer the opinions herein, is attached hereto. In general, the bases for Dr. Catlin's opinions herein are his formal education, his work experience, his research, and his continuing education in the form of remaining abreast of issues related to performance-enhancing substances in athletics via reading current literature in the field and attending educational classes, seminars, etc.

B. Areas of Expected Testimony

Dr. Catlin will testify to all of the areas referenced in his grand jury testimony, including the following:

Dr. Catlin will testify that the UCLA Olympic Lab performed the testing on the urine sample collected from the defendant by Major League Baseball (MLB). He will testify to the results of those tests and their meaning, including the use and results of the Carbon Isotope Ratio test. Dr. Catlin will testify that the results of the test were that he found exogenous testosterone, THG, and clomid in the 2003 sample. He will also testify that THG was never commercially available from any source (other than Patrick Arnold) during the time of the defendant's THG-positive urine samples. As such, Dr. Catlin's testimony also includes statements as a percipient witness.

Larry D. Bowers, Ph.D., DABC

A. Qualifications

Dr. Bowers is employed as the Senior Managing Director, Technical and Information Resources, for the United States Anti Doping Agency (USADA). A copy of Dr. Bowers' curriculum vitae, which details his qualifications to offer the opinions herein, is attached hereto. In addition to the qualifications set forth in the CV, Dr. Bowers held a DEA license for eight (8) years prior to joining USADA in 2000. In general, the bases for Dr. Bowers' opinions herein are his formal education, his work experience, his research (including scientific experiments), and his continuing education in the form of remaining abreast of issues related to performance-enhancing substances in athletics via reading current literature in the field and attending educational classes, seminars, etc.

B. Areas of Expected Testimony

The United States will seek to offer Dr. Bowers' testimony for the following areas relevant to the trial:

Dr. Bowers will testify that it is his opinion that testosterone, human growth hormone (HGH), insulin, and erythropoietin (EPO), are performance-enhancing substances. He will also testify that:

1. Testosterone is a chemical that causes muscle growth and retention of muscle. It can make a person stronger and it can benefit a person's ability to recover, i.e. it can enable a person to work muscles more often and harder than without the assistance of testosterone.
2. HGH can cause changes to the body by itself or, in connection with other substances, e.g. anabolic steroids and insulin, that can be responsible for the growth of a large number of bodily systems, e.g. muscles and bones. Similar to testosterone, HGH can enhance athletic performance by promoting muscle growth and speeding recovery time for muscles after they have been utilized.
3. Insulin is a chemical that assists the body to get sugar and other constituents into the cell. As a performance-enhancing substance, insulin is used to regenerate energy stores in the cell and to prevent muscle breakdown. Insulin is frequently used in conjunction with another substance, such as HGH. HGH increases muscle growth while insulin decreases muscle breakdown, resulting in faster recovery and more muscle accumulation than either substance alone.
4. EPO is a hormone that regulates the number of red blood cells in the blood system. If EPO in addition to the amount naturally produced by the body is administered into the body, it can increase the number of red blood cells in a body's blood system. The performance-enhancing aspect of such an effect is that a body is thereafter able to better transport oxygen to muscles, which can make the muscles more effective in making energy. The benefits of EPO are that a person may experience improved endurance and energy. EPO can enhance a person's ability to train for athletic performances and to perform in athletic competitions.

Academic Curriculum Vitae**DON H. CATLIN, M.D.****COMMUNICATIONS:**

Telephone: ADR 310-482-6925 (messages taken at UCLA 310-825-2635)

Facsimile: ADR 310-482-6929

Emails: dcatlin@antidopingresearch.org or dcatlin@ucla.edu

Web site www.antidopingresearch.org

Address: Anti-Doping Research
3873 Grand View Blvd.
Los Angeles, Ca. 90066

PERSONAL HISTORY:

Address: 12415 Rochedale Lane, Los Angeles, CA. 90049

Date of Birth: June 4, 1938 Connecticut

Marital status: Widowed, 1989

Children: Bryce 1974, Oliver 1976

EDUCATION and TRAINING:

Yale University	B.A.	1960
University of Rochester School of Medicine	M.D.	1965
University of California Los Angeles Department of Medicine	I Internship II Residency	1965-1966 1966-1967
University of Vermont Department of Medicine	III Residency	1967-1968

EDUCATION and TRAINING: (continued)

PRESENT POSITIONS: UNIVERSITY OF CALIFORNIA, LOS ANGELES

Professor of Molecular and Medical Pharmacology 2002 - 2007 -
Professor Emeritus of Molecular and Medical Pharmacology 2007 -
Founder and Director, UCLA Olympic Analytical Laboratory 1982 - 2007

PRESENT POSITIONS: LOCAL, NATIONAL AND INTERNATIONAL

Anti-Doping Research Institute (Not for Profit)
President 2006
International Olympic Committee (IOC)
Member, Medical Commission 1989 -
Chair, Science and Medicine Committee 2003 -
World Anti-Doping Agency (WADA)
Laboratory Director 2000 - 2007
Member Medicine and Science Committee 2006 - 2008
Los Angeles Sheriffs Department, Medical Review Officer 1991 -

CERTIFICATION:

License to Practice Medicine: California 1965-
Vermont 1967 - 1990
District of Columbia 1968 - 1980
Diplomate: American Board of Internal Medicine 1970
Board Certified, Internal Medicine

UCLA OLYMPIC ANALYTICAL LABORATORY CERTIFICATION:

The International Olympic Committee 1983 -
College of American Pathologists 1993-2001
International Organization for Standardization (ISO) 1999 -

UCLA OLYMPIC ANALYTICAL LABORATORY CERTIFICATION: (continued)

U.S. Department of Defense 2000 -

World Anti-Doping Agency (WADA) 2004 -

PAST ACADEMIC POSITIONS:

University of California, Los Angeles

Department of Medicine
 Assistant Professor 1972-1979
 Associate Professor 1979-2001

Department of Pharmacology
 Assistant Professor 1972-1979
 Associate Professor 1979-2001

PAST POSITIONS:

United States Army Medical Corps 1969-1972

Walter Reed Army Institute of Research, Washington, D.C.,
 Captain 1969-1970, Major (retired, 1972)
 Department of Medicine, Gastroenterology

District of Columbia, Department of Health

Director, Substance Treatment Clinic 1971-1972

University Committees

Physicians Health Committee, UCLA Medical Center 1991 - 2007

International Federation of Clinical Chemistry:

Committee on Laboratory Analysis of Drugs of Abuse, Chairman 1988-1996

International Olympic Committee

Subcommission on Out-of-Competition Testing. 1991-1999
 Various working groups

PAST POSITIONS (continued):

United States Olympic Committee

Committee on Substance Abuse, Research and Education	
Founding Chairman	1985-1989
Member	1989-2000

International Doping Control Working Group, U.S. representative. 1987-1999

Soviet-American Joint Drug Education & Anti-doping Commission 1988-1992

National Collegiate Athletic Association:

Various committees	1985-2001
--------------------	-----------

Council of Europe, Invited Delegate:	1987-1994
--------------------------------------	-----------

PROFESSIONAL ACTIVITIES: PAST MEMBERSHIP

The Androgen Society

California Medical Association

Western Society for Clinical Research

American Association for the Advancement of Science

American Chemical Society

International Federation of Clinical Chemistry

American Association for Clinical Chemistry

U.S. Pharmacopeial Convention

PROFESSIONAL ACTIVITIES: ad hoc CONSULTANT

Editorial Service:	Various scientific journals including: JAMA, Nature, Steroids, J Clinical Endocrinology and Metabolism, and J Mass Spectrometry
--------------------	---------------------------------------------------------------------------------------------------------------------------------

Editorial Board:	The Georgia Tech Sports Medicine and Performance Newsletter Drugs and sport reviewer for Clinical Chemistry, Nature and others
------------------	-----------------------------------------------------------------------------------------------------------------------------------

PROFESSIONAL ACTIVITIES: ad hoc CONSULTANT (continued)

National Institute on Substance Abuse
 Health and Human Services
 Food and Drug Administration
 Office of National Drug Control Policy
 Drug Enforcement Agency
 Department of Justice
 Armed Forces Institute of Pathology

State of California: Department of Alcohol and Drug Programs, Health and Welfare Agency
 Department of Health Services, Board of Medical Quality Assurance
 California Horse Racing Board
 State Compensation Insurance Fund, Department of Justice
 Department of Education
 Lawrence Livermore Laboratories

City of Los Angeles: Chief Medical Examiner-Coroner
 City Attorney's Office
 Los Angeles Police Commission

Sport Organizations: National Collegiate Athletic Association

United States Olympic Committee and all USOC National Sport
 Governing Bodies such as USA Track and Field

International Sport Federations, various and including: International
 Amateur Athletic Federation, Cycling (UCI), soccer (FIFA)

National Football League

National Strength and Conditioning Association

Various colleges and universities

Major Media Consultant on Drugs and Sport:

New York Times; Washington Post; Los Angeles Times; British Broadcasting
 Corporation; London Times; Sports Illustrated; ABC, CBS, and NBC Sports;
 Turner Sports; ESPN Sports; Time, National Public Radio, and others.

HONORS AND SPECIAL AWARDS:

Alpha Omega Alpha Honor Medical Society

1965

HONORS AND SPECIAL AWARDS: (continued)

International Olympic Committee:

Distinguished Sports Medicine Physician Award 1989

National Strength and Conditioning Association:

Presidents Award 1990

Los Angeles Times

100 Most Influential Persons in Sport 1990

American Society of Mass Spectrometry

Plenary Speaker 1995

Plenary Speaker 2005

Sportsman of the Year, 2003

Chicago Tribune 2003

INVITED LECTURES: INTERNATIONAL AND NATIONAL, since 1990

Main Topics: 1. Clinical Uses of Anabolic Androgenic Steroids; 2. Adverse Effects of Anabolic Steroids; 3. Testing for Anabolic Steroids; 4. Antidoping Activities in the U.S.; 5. Carbon Isotope Ratio Techniques; 6) Pharmacology of Drugs of Abuse; 7) Tetrahydrogestrinone.

American Society of Addiction Medicine, Annual Meeting. Boston, MA November, 1990.

Council of Europe, U.S. delegate. Anti-doping Convention. Strasbourg, France. June, 1991.

National Collegiate Athletic Association (NCAA). Annual Conference for Physicians.
Sun Valley, Idaho. June 24, 1991.

U.S. Drug Enforcement Agency - Symposium on Anabolic steroids. Boston, MA. July 1991.

Surgeon General: U.S. Department of Defense. Fort Sam Houston, Texas. August, 1991.

Third Permanent World Conference on Drugs in Sport. Bergen, Norway. September, 1991.

American Society of Addiction Medicine. Cleveland, Ohio. April, 1991.

Keynote Speaker: Analytical Considerations in doping Control in Olympic and Sports Medicine.

Federation for Analytical Chemistry and Spectroscopy Society. Anaheim, CA. October, 1991.

INVITED LECTURES: INTERNATIONAL AND NATIONAL, since 1990 (continued)

United States Olympic Committee: Olympic Congress of the USA. Colorado Springs, Co. November, 1991.

Soviet Sportsmedicine in cooperation with Soviet-American Joint Commission on Drug Abuse. Moscow, Soviet Union December 1991.

Pittsburgh Conference. (GC-MS of Anabolic Steroids) New Orleans, LA. March, 1992.

National Football League. Washington, D.C. and Denver, CO. May, 1992.

Federal Bureau of Investigation. Toxicology Symposium. Quantico, VA. June, 1992.

Council of Europe, Anti-Doping Convention. Strasbourg, France. December, 1992.

Central American Caribbean Scientific Congress. San Juan, Puerto Rico. March, 1993.

Symposium: Control of Doping with Anabolic Steroids. London, U.K. September, 1993.

Fourth Permanent World Conference on Anti-doping in Sport. London, UK. September, 1993.

Centennial of the International Olympic Committee. Paris, France. August, 1994.

Royal Pharmaceutical Society of Great Britain. 131st British Pharmaceutical Conference. London, England. September, 1994.

Second International Androgen Workshop. Agency for International Development. Long Beach. February 1995.

XIIth Doping Control Seminar. Cologne, Germany March, 1995.

Plenary Speaker: American Society of Mass Spectrometry. Atlanta, Georgia. May, 1995.

Seminar, Hewlett Packard. Palo Alto, CA. May, 1995.

National Association of Athletic Trainers. Indianapolis, In. June, 1995.

University of Oregon. Ashland, Oregon August, 1995.

Australian Society of Mass Spectrometry. University of New South Wales, Sidney, Australia September, 1995.

World Congress of Sports Medicine. Atlanta, Georgia. September, 1995.

INVITED LECTURES: INTERNATIONAL AND NATIONAL, since 1990 (continued)

University of Rochester, October, 1995.

HPLC Annual Meeting, keynote speaker, May, 1996.

XVIth World Congress of Clinical Chemistry. London, UK. July, 1996.

American College of Sports Medicine, June, Orlando, June, 1998.

USOC Olympic Congress, Phoenix, Arizona. November, 1998.

Australian International Symposium on Analytical Science. Melbourne, Australia. July, 1999.

Australian Sports Medicine Association, Sydney, Australia. July, 1999.

American Medical Society for Sports Medicine, San Diego, March, 2000.

American College of Sports Medicine, Indianapolis, May, 2000.

The Endocrine Society, Toronto, Canada, June, 2000.

American Orthopedic Society for Sports Medicine, Los Angeles, March, 2002.

British Medical Association, London, UK, April, 2002.

American Association for the Advancement of Science (AAAS) Current Pharmacological Doping Methods and Banned Substances. Seattle, WA, February 2004.

International Association of Horseracing Chemists and Veterinarians, Dubai, UAR March, 2004.

American Society of Andrology. Use, Abuse, and Addiction to Anabolic Steroids. Baltimore, MD, April 2004.

American College of Sports Medicine. Indianapolis, IN, June 2004.

The Endocrine Society - Science Writers Conference. New York, NY, December 2005.

Neutracon Supplement Meeting. February 2006

Annual Meeting of American Society of Clinical Pathologists, Las Vegas, Nevada, October 2006

World Boxing Council - April, 2007 Cancun Mexico.

Title: Use, Abuse, and Addiction to Anabolic Steroids.

Title 2: Role of blood doping and erythropoietins in sport.

INVITED LECTURES: INTERNATIONAL AND NATIONAL, since 1990 (continued)

Saratoga Institute on Racing and Gaming Law, Albany Law School, August 7, 2007

Title: The Human Testing Experience Applied to Testing Race Horses.

INVITED LECTURES: UCLA AND CALIFORNIA, since 1990

California State Department of Health Services: Public Health Grand Rounds. March, 1990.

UCLA Neuropsychiatric Institute: Substance Abuse Focus Group. UCLA. May, 1990.

Symposium: Sports Alcohol and Other Drugs. Oakland, CA. October, 1990.

Grand Rounds. Childrens Hospital, Oakland, CA. August, 1990.

Pacific Interurban Clinical Club. Los Angeles, CA. November 3, 1990.

Obstetrics and Gynecology Endocrinology Seminar. UCLA. January, 1991.

California Society of Addiction Medicine. San Francisco, CA. October, 1991.

Los Angeles Police Commission. Los Angeles, CA. March, 1992.

Saint John's Hospital and Health Center. Santa Monica, CA. September, 1992.

California Society of Addiction Medicine. Anaheim, CA. November, 1992.

Obstetrics and Gynecology Assembly of Southern California. Los Angeles, CA. February, 1993.

World Cup Soccer, Federation International Football Association. Los Angeles, CA. April 1994.

UCLA School of Medicine - Interdepartmental Conference. UCLA. May, 1994.

Grand Rounds, Hoag Memorial Hospital, September, 1995.

Harbor-UCLA Endocrine Grand Rounds, October, 1995.

Wadsworth Veterans Administration, Endocrinology Grand Rounds, March, 1996.

Division of Family Practice, UCLA, October, 1996.

Harbor-UCLA Endocrine Grand Rounds, April, 1998.

INVITED LECTURES: UCLA AND CALIFORNIA, since 1990 (continued)

UCLA School of Medicine, Grand Rounds, June, 2002.

Solvay Course on Androgens Manhattan Beach, April, 2003.

American Association for the Advancement of Science, Seattle, February, 2004.

UCLA Department of Pediatrics, Endocrinology, Grand Rounds, October, 2004.

UCLA-Wadsworth, Department of Endocrinology, Grand Rounds, January, 2005.

Amgen, Thousand Oaks, CA. Drugs and Sports, Special Seminar, Internal video to all Amgen sites. December 2006

California Society of Addiction Medicine, State of the Art Conference, October, 2007
Title: The Pharmacology and Testing of Enhanced Athletic Performance.

California Los Verdes Mens Club, October, 2007.
Title: Can cheaters be stopped?

Manatt Law Firm. CLE: Drugs, Sport, and the Law. Internal video to all Manatt offices.
January 11, 2008

SEMINARS & SYMPOSIA ORGANIZED AND PRESENTED, since 1989

Chairperson and Principal Speaker: CME Course on Drugs in Sport for Physicians associated with United States Olympic Committee.
UCLA Medical Center, Los Angeles, CA. May 1989.

Second Permanent World Conference on Drugs in Sport.
Member of Organizing Committee
Moscow, USSR. September, 1989.

Department of Defense
Two day seminar on Anabolic steroids.
The Pentagon, November 16-17, 1990.

United States Olympic Committee (USOC).
Chair UCLA CME Course on Drugs in Sport for Physicians.
Colorado Springs, Colorado. May 18-20, 1991.

Third Permanent World Conference on Drugs in Sport.
Member of Organizing Committee and Speaker
Bergen, Norway. September 20-26, 1991.

SEMINARS & SYMPOSIA ORGANIZED AND PRESENTED, since 1989

United States Olympic Committee.
Co-Chair UCLA CME course on Drugs, Athletes, and Testing.
Colorado Springs, CO. March 10-12, 1993.

Fourth Permanent World Conference on Drugs in Sport.
Member of Organizing Committee and Speaker
London, England. September 4-8, 1991.

United States Olympic Committee.
Co-Chair CME course on Drugs, Athletes, and Testing.
Colorado Springs, CO. June 3-5, 1994.

United States Anti-Doping Agency.
Co-Sponsor Conference on Carbon Isotope Ratio Techniques
Los Angeles, CA. August, 2003.

PRINCIPAL CONSULTANT TO MAJOR SPORT EVENTS:

Summer Olympic Games of Los Angeles, 1984
Director of Laboratory

World University Games.
Buffalo, NY. 1991-1993.

Goodwill Games, Member of Medical Commission
Seattle, Washington 1990.
Director of Laboratory

Summer Olympic Games of Seoul, 1988
Pan American Games, Member of Medical Commission
Havana, Cuba July 1991.

Winter Olympic Games of Albertville, 1992.
Member of Medical Commission
Albertville, France. 1991-1992.

Summer Olympic Games of Barcelona, 1992.
Member of Medical Commission
Barcelona, Spain. 1990-1992.

Americas Cup Race, 1992, San Diego, CA. 1992.

PRINCIPAL CONSULTANT TO MAJOR SPORT EVENTS (continued):

Central American and Caribbean Games
Member of Medical Commission
Director of Laboratory/Transfer of Accreditation
San Juan, Puerto Rico 1992-1993.

Winter Olympic Games of Lillehammer, 1994
Member of Medical Commission
Lillehammer, Norway. 1991-1992.

World Cup Soccer, FIFA, Director of Laboratory
United States, 1991-1994.

Goodwill Games, St. Petersburg, Russia 1994.

Olympic Games of Atlanta, 1996
Atlanta, Georgia. 1992-1996.
Director of Steroid Testing Laboratory

Winter Olympic Games of Nagano, 1998
Member of IOC Medical Commission
Nagano, Japan

Summer Olympic Games of Sydney, 2000
Member of IOC Medical Commission
Sydney, Australia

Winter Olympic Games of Salt Lake, 2002
Member of IOC Medical Commission
Director of Laboratory

Summer Olympic Games of Athens, 2004
Member of IOC Medical Commission

Winter Olympic Games of Torino, 2006
Member of IOC Medical Commission

Summer Olympic Games of Beijing, 2008
Member of IOC Medical Commission

SPORT CONSULTATIONS ON LEGAL MATTERS

CASES INVOLVE TESTING AND MEDICINE, since 1990 (continued)

United States Olympic Committee National Governing Sport Bodies: 1984-2001.

Principal consultant from 1984 - 1999

Examples:

Slaney vs IAAF

United States Anti-Doping Agency

Principal consultant from inception of Agency in 2000 until 2007

Examples:

USADA v. Gatlin

USADA v. Tammy Thomas

USADA v. Jovanovich

USADA v. Chamber

USADA v. Landis

International Olympic Committee, Court of Arbitration for Sport

Arbitral Award: CAS 2002/A/370 LAZUTINA v/ IOC

Arbitral Award: CAS 2002/A/374 MUEHLEGG v/ IOC

Arbitral Award: CAS 2002/A/376 BAXTER v/ IOC

Arbitral Award: CAS 2002/A/389-393 Austrian Ski Team v/ IOC

Arbitral Award: CAS 2004/xxxxx ZACHARY LUND v/ IOC

Arbitral Award: CAS 2007/A/1286/ JOHANNES EDER v/ IOC

Arbitral Award: CAS 2007/A/1288/ MARTIN TAUBER v/ IOC

Arbitral Award: CAS 2007/A/1289/ JURGEN PINTER v/ IOC

United States Department of Justice

Balco cases: two Grand Jury appearances

Performed chemistry analysis for several cases

Known pending case: United States v Thomas, Case 06-0803 SI

Chambers vs. UK Athletics: Tetrahydrogestrinone, 2004.

National Football League, various, 1989 - 2006

National Collegiate Athletic Association 1986-2006

Supplement Superdrol (methasterone) causes severe hepatic & renal failure in two young men

Att: Lawrence Cook

Supplement 5HTP alleged to contain peak X, a toxins.

Maker: Neutraceutical Corporation

PUBLICATIONS:

1. Powell DW, Plotkin GR, Maenza RM, Solberg LI, Catlin DH, Formal SB. Experimental diarrhea I. Intestinal water and electrolyte transport in rat salmonella enterocolitis. *Gastroenterology* 1971;60:1053-1064.
2. Powell DW, Plotkin GR, Solberg LI, Catlin DH, Maenza RM, Formal SB. Experimental diarrhea II. Glucose-stimulated sodium and water transport in rat salmonella enterocolitis. *Gastroenterology* 1971;60:1065-1075.
3. Powell DW, Solberg LI, Plotkin GR, Catlin DH, Maenza RM, Formal SB. Experimental diarrhea III. Bicarbonate transport in rat salmonella enterocolitis. *Gastroenterology* 1971; 60:1076-1086.
4. Adler FL, Liu CT, Catlin DH. A rapid serological screening test for morphine. Abstracts of Federation Proceedings, 1972.
5. Catlin DH, Cleeland R, Craves F, Grunberg E. A rapid and sensitive radioimmunoassay for detection of morphine in urine and serum. Abstracts of the American Public Health Association Meeting, 1972.
6. Adler FL, Liu CT, Catlin DH. Immunological studies on heroin addiction I. Methodology and application of a hemagglutination-inhibition test for detection of morphine. *Clin Immunol Immunopathol* 1972;1:53-68.
7. Catlin DH, Cleeland R, Grunberg E. A sensitive, rapid radioimmunoassay for morphine and immunologically related substances in urine and serum. *Clin Chem* 1973;19:216-220.
8. Catlin DH, Adler FL, Liu CT. Immunological studies on heroin addiction II. Applications of a sensitive hemagglutination-inhibition test for detecting morphine to diagnostic problems in chronic heroin addiction. *Clin Immunol Immunopathol* 1973;1:446-455.
9. Catlin DH. Urine testing: A comparison of five current methods for detecting morphine. *Am J Clin Pathol* 1973; 60:719-728.
10. Catlin DH. A Guide to Urine Testing for Drugs of Abuse. Washington, DC: U.S. Government Printing Office, 1973.
11. Catlin DH. Evaluation and clinical application of the immunoassays for morphine. In: Sunshine I, Mule SJ, Braude MC, eds. Immunoassays for Drugs Subject to Abuse. Cleveland: CRC Press, 1974.

PUBLICATIONS (Continued):

12. Gorodetsky CW, Angel CR, Beach DJ, Catlin DH, Yeh S. Validity of screening methods for drugs of abuse in biological fluids. I. Heroin in urine. *Clin Pharmacol Ther* 1974; 15:461-472.
13. Catlin DH, Jenden DJ. Estimation of morphine in biological samples by immunoextraction and GC/MS. Abstracts International Congress of Pharmacology, 6th Proceeding, Helsinki, Finland, 1975.
14. Catlin DH, Schaeffer JC, Fischer JF. Production and characterization of antibodies to meperidine. *Res Commun Chem Path Pharmacol* 1975;11:245-256.
15. Clausen JL, Hill RN, Liewen MB, Catlin DH. Arterial and venous lidocaine levels during anesthesia of upper and lower airways. *Clin Res* 1976; 24:159A.
16. Catlin DH, Schaeffer JC, Liewen MB. 2-Diazomorphine directed anti-serum: Determination of morphine in brain after naloxone challenge in morphine pellet implantation in mice. *Life Sci* 1977;20:123-132.
17. Catlin DH, Liewen MB, Schaeffer JC. Brain levels of morphine in mice following removal of a morphine pellet and naloxone challenge: No evidence for displacement. *Life Sci* 1977; 20:133-139.
18. Catlin DH. Pharmacokinetics of morphine by radioimmunoassay: The influence of immunochemical factors. *J Pharmacol Exp Ther* 1977;200:224-235.
19. Dum J, Meyer G, Holtt V, Herz A, Catlin DH. Inability of naloxone to change morphine brain levels in tolerant mice. *Eur J Pharmacol* 1977;46:165-170.
20. Catlin DH, Hui KK, Loh HH, Li CH. Pharmacologic activity of beta-endorphin in man. *Commun Psychopharmacol* 1977;1:493-500.
21. Catlin DH, Hui KK, Loh HH, Li CH. Beta-endorphin: Subjective and objective effects during acute narcotic abstinence in man. *Adv Biochem Psychopharmacol* 1978;18:341-350.
22. Catlin DH, George R, Li CH. Beta-endorphin: Pharmacologic and behavioral activity in cats after low intravenous doses. *Life Sci* 1978;23:2147-2154.
23. Gorelick DA, Catlin DH, George R, Li CH. Beta-endorphin is behaviorally active in rats after chronic intravenous administration. *Pharmacol Biochem Behav* 1978;9:385-386.
24. Catlin DH, Hui KK, Loh HH, Li CH. Beta-endorphin: Initial clinical studies. In: Usdin E, Kline NS, Bunney WE Jr, eds. Endorphins in Mental Health Research. New York: MacMillan Press, 1979, pp. 535-544.

PUBLICATIONS (Continued):

25. Hui KK, Catlin DH, Conolly ME, Li CH. Human beta-endorphin, cyclic AMP and the human lymphocyte beta-adreno-receptor. World Conference on Clinical Pharmacology and Therapeutics, London, August 3-9, 1980. (Abstract)
26. Catlin DH, Gorelick DA, Gerner RH, Hui KK, Li CH. Clinical studies with human beta-endorphin. In: Beers RF, Bassett EG, eds. Polypeptide Hormones, No. 12. New York: Raven Press, 1980:337-346.
27. Catlin DH, Gorelick DA, Gerner RH, Hui KK, Li CH. Clinical effects of beta-endorphin infusions. *Adv Biochem Psychopharmacol* 1980;22:465-472.
28. Catlin DH, Poland RE, Gorelick DA, Gerner RH, Hui KK, Rubin RT, Li CH. Intravenous infusion of beta-endorphin increases serum prolactin, but not growth hormone or cortisol in depressed subjects and withdrawing methadone addicts. *J Clin Endocrinol Metab* 1980; 50:1021-1025.
29. Bajorek JC, Catlin DH, Lomax P. Anticonvulsant activity of beta-endorphin in the seizure sensitive mongolian gerbil. Society for Neurosciences, Cincinnati, Ohio. November, 1980. (Abstract)
30. Gerner RH, Catlin DH, Gorelick DA, Hui KK, Li CH. Beta-endorphin: Intravenous infusion causes behavioral change in psychiatric in-patients. *Arch Gen Psychiatry* 1980;37:642-647.
31. Catlin DH, Smith RA, Samuels AI. ¹⁴C-Ribavirin: Distribution and pharmacokinetic studies in rats, baboons, and man. In: Smith RA, Kirkpatrick W, eds. Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press, 1980, pp. 83-98.
32. Robinson JS, Catlin DH, Barrett CT. Withdrawal from methadone by breast feeding. In: Stern L, ed. Intensive Care in the Newborn. New York: Masson Publishers, 1980, pp. 213-218.
33. Gerner RH, Gorelick DA, Catlin DH, Li CH. Behavioral effects of beta-endorphin in depression and schizophrenia. In: Shah NS, Donald AG, eds. Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications. New York: Plenum Press, 1980.
34. Catlin DH, Gerner RH, Gorelick DA. Beta-endorphin: Behavioral effects of single and multiple infusions - Measurement of CSF levels. Third World Congress of Biological Psychiatry, Stockholm, Sweden, 1980; S56 (Abstract).
35. Gorelick DA, Catlin DH, Gerner RH. Beta-endorphin studies in psychiatric patients. In: Emrich HM, ed. Modern Problems in Pharmacopsychiatry, Vol 17. Basel, Switzerland: S. Karger, 1981:236-245.

PUBLICATIONS (Continued):

36. Catlin DH, Gorelick DA, Gerner RH. Studies of beta-endorphin in patients with pain and drug addiction. In: Li CH, ed. Hormonal Proteins and Peptides, Vol 10. New York: Academic Press, 1981:311-338.
37. Bajorek JG, Lee RJ, Catlin DH, Lomax R. Effects of beta-endorphin on experimentally induced seizures in mice. *Proc West Pharmacol Soc* 1981;24:315-317.
38. Catlin DH, Gorelick DA, Gerner DH. Clinical pharmacology of beta-endorphin in depression and schizophrenia. In: Verebey K, ed. Annals of the New York Academy of Sciences. New York: Academy of Sciences, 1982:434-447.
39. Gerner RH, Gorelick DA, Catlin DH, Sharp B. Endorphins: CSF levels and multidose studies in psychiatric subjects. In: Perris C, Struwe G, Jansson B, eds. Biological Psychiatry 1981. Elsevier: North Holland Biomedical Press, 1981:386-389.
40. Gerner RH, Sharp B, Catlin DH. Peripherally administered beta-endorphin increases cerebrospinal fluid endorphin immunoreactivity. *J Clin Endocrinol Metab* 1982;55:358-360.
41. Catlin DH. Pharmacokinetics. In: Bevan JA, Thompson JH, eds. Essentials of Pharmacology, 3rd ed. New York: Harper and Row, 1983:46-61.
42. Catlin DH. Opioids: Agonists, antagonists, and mixed antagonist-agonists. In: Bevan JA, Thompson JH, eds. Essentials of Pharmacology, 3rd ed. New York: Harper and Row, 1983:318-330.
43. Strauss RH, Wright JE, Finerman GAM, Catlin DH. Side effects of anabolic steroids in weight-trained men. *Physician and Sports Medicine* 1983; 11:87-96.
44. Batzdorf U, Catlin DH. Pain syndromes in malignant disease. In: Haskell CM, ed. Cancer Treatment, 2nd ed. New York: W.B. Saunders, 1985:928-940.
45. Wright J, Bahrke M, Strauss R, Catlin DH. Psychological states, behavioral changes and somatic perception accompanying anabolic steroid usage. American College of Sports Medicine, 1985. (Abstract).
46. Strauss RH, Catlin DH, Morgan JP, Murphy RJ, Murray TH, Puffer JC, Voy RO. Drug testing in sports: A round table. *Physician and Sports Medicine* 1985;13:69-82.
47. Catlin DH. Detection of drug use by athletes. In: Strauss R, ed. Drugs and Performance in Sports. New York: W.B. Saunders, 1987:103-120.

PUBLICATIONS (Continued):

48. Catlin DH, Hatton CK. Clinical pharmacology of androgenic anabolic steroids (AAS) in sport. Acta Pharmacol et Toxicol 1986 (Suppl V)(Abstract 16).
49. Catlin DH, Hatton CK. Identification of boldenone, a veterinarian androgenic anabolic steroid, in the urine of bodybuilders. Acta Pharmacol et Toxicol 1986 (Suppl V) (Abstract 349).
50. Kammerer RC, Merdink J, Jagels M, Hui K, Catlin DH. Fluoxymesterone metabolism in man. 192nd American Chemical Society Meeting, Anaheim, California, September, 1986. (Abstract).
51. Catlin DH. Adverse effects of blood transfusions. Olympic Review 1987; 231:37-41.
52. Catlin DH, Kammerer RC, Hatton CK, Sekera MH, Merdink JM. Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984. Clin Chem 1987;33:319-327.
53. Hatton CK, Catlin DH. Detection of androgenic anabolic steroids in urine. Clinics in Laboratory Medicine 1987;7:655-668.
54. Elliot DL, Goldberg L, Kuehl KS, Catlin DH. Characteristics of anabolic-androgenic steroid-free competitive male and female bodybuilders. Physician and Sports Med 1987; 15:169-179.
55. Hatton CK, Catlin DH. Urinary steroid profiles of athletes. 35th American Society Mass Spectrometry, Denver Colorado, May 24-29, 1987. (Abstract).
56. Barriere SL, Orlando PL, Catlin DH. Pharmacokinetic disposition and pharmacodynamic effects of IV Ciprofloxacin (C) and Azlocillin (A) given alone and in combination to healthy subjects. Abstracts of the 1988 ICAAC, 1988:245 (Abstract 768).
57. Catlin DH and Hatton CK. Introduction to and use of frequency distributions to distinguish between urinary 19-norandrosterone arising from the administration of norethisterone or that of 19-noresterone. First International Symposium on Drugs in Competitive Athletics, Brioni, May 29-June 2, 1988. (Abstract).
58. Catlin DH. Drugs in competitive athletics. First International Symposium on Drugs in Competitive Athletics, Brioni, May 29-June 2, 1988. (Abstract).
59. Brower KJ, Eliopoulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic-androgenic steroids in eight weight lifters. Am J Psychiat 1990;147:510-512.
60. Batzdorf U, Catlin DH. Pain syndromes in malignant disease. In: Haskell CM, ed. Cancer Treatments, 3rd ed. New York: W.B. Saunders, 1990:874-883.

PUBLICATIONS (Continued):

61. Barriere SL, Catlin DH, Orlando PL, Hindler JA, Noe A, Frost RW. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. *Antimicrobial Agents and Chemotherapy* 1990;34:823-826.
62. Edmond JE, Korsak RA, Morrow JW, Torok-Both G, Catlin DH. The origin of cholesterol in brain of the developing rat. *Fed Am Soc Exp Biol* 1990. (Abstract).
63. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. *Adv Int Med* 1991;36:399-424.
64. Catlin DH. Pharmacokinetics and interpretation of test results. *Fresenius J Anal Chem* 1990; 337:50.
65. Bahrke MS, Wright JE, O'Connor JS, Strauss RH, Catlin DH. Selected psychological characteristics of anabolic-androgenic steroid users (Letter to the Editor). *N Engl J Med* 1990;323:834-835.
66. Kammerer RC, Merdink J, Jagels M, Catlin DH, Hui, KK. Testing for fluoxymesterone (Halotestin) administration to man: Identification of urinary metabolites by gas chromatography-mass spectrometry. *J Steroid Biochem* 1990;36:659-666.
67. Brower KJ, Catlin DH, Blow FC, Eliopoulos GA, Beresford TP. Clinical assessment and urine testing for anabolic androgenic steroid abuse and dependence. *Am J Drug Alcohol Abuse* 1991;17:161-172.
68. Catlin DH, Starcevic B. HPLC method for the assay of creatinine in urine. *J Liquid Chromatog* 1991;14:2399-2408.
69. Hatton CK, Catlin DH, Straus PW, Starcevic SH. Urinary steroid profiles: A longitudinal study. 38th ASMS Conference on Mass Spectrometry and Allied Topics, Tucson, Arizona, June 3-8, 1990. (Extended Abstract)
70. Edmond J, Korsak RA, Morrow JW, Torok-Both G, Catlin DH. Dietary cholesterol and the origin of cholesterol in the brain of developing rats. *J Nutr* 1991;121:1323-1330.
71. Thompson PD, Sadaniantz A, Cullinane MS, Bodziony KS, Catlin DH, Torok-Both GT, Douglas PS. Left ventricular function is not impaired in weightlifters using anabolic steroids. *J Am Coll Cardiol* 1992;19:278-282.
72. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid usage. *Am J Sports Med* 1992;20:717-724.

PUBLICATIONS (Continued):

73. Catlin DH. Anabolic steroids monitoring - Clinical interpretation and analytical challenges. 1992 Pittsburgh Conference and Exposition, New Orleans, March 9-12, 1992. (Abstract 026).
74. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry). *Clinica Chimica Acta* 1992;207:S13-S26.
- 74a. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). *J Auto Chem* 1992;14:85-92.
- 74b. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). *Ann Biol Clin* 1992;50:359-366.
- 74c. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). *Europ J Clin Chem Clin Biochem.* 1993;41-49.
- 74d. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). *J Internat Fed Clin Chem.* 1993
75. Catlin DH. Analytical consideration in doping control in Olympic sports medicine - Challenges for the 90's. Federation of Analytical Chemistry and Spectroscopy Studies' Eighteenth Annual Meeting, Anaheim, California, October 6-11, 1991. (Abstract 20).
76. Catlin DH, Cowan DA. Detecting testosterone administration. *Clin Chem* 1992;38:1685-1686. (Editorial)
77. Thompson PD, Zmuda JM, Catlin DH. Use of anabolic steroids among adolescents. *N Engl J Med* 1993;329:888-889. (Letter to the editor)
78. Catlin DH, Wright J, Pope H Jr, Liggett M. Assessing the threat of anabolic steroids. Discussion. Ed: Strauss RH. *Phys and Sportsmed* 1993;21:37-44.
- 78a. Catlin DH, Wright J, Pope H Jr, Liggett M. Assessing the threat of anabolic steroids. Discussion. Ed: Strauss RH. Reprinted in *Muscle and Fitness*. April, 1994. (Reprint)
79. Zmuda JM, Fahrenbach MC, Younkin BT, Bausserman LL, Terry RB, Catlin DH, Thompson PD. The effect of testosterone aromatization on high-density lipoprotein cholesterol and postheparin lipolytic activity. *J Clin Endocrinol Metab* 1993;42:446-450.

PUBLICATIONS (Continued):

80. Catlin DH, Sekera M, Adelman DC. Exfoliative dermatitis associated with ingestion of an herbal product. *Western J Med* 1993;159:491-493.
81. Catlin DH, Salehian B, Boghosian T, Swerdloff RS, Wang C. Changes in urinary testosterone and epitestosterone after sublingual testosterone cyclodextrin administration. *Clinical Research*, 1993; vol 42. (Abstract).
82. Catlin DH. Testing succeeds in keeping sports clean. Editorial in *USA Today*. October 12, 1994 p8C.
83. Catlin DH. Anabolic steroids. In DeGroot LJ, ed. Endocrinology, 3rd ed. Orlando, Florida: W.B. Saunders Co. 1995:2362-2376.
84. Catlin DH. Ratio of testosterone to epitestosterone in urine: Clinical and analytical considerations in the context of doping control. In: Cowan DA, Kicman AT, eds. Control of Doping with Anabolic Agents: Proceedings of the Scientific Meeting of the 4th Permanent World Conference on Antidoping in Sport, London. Caligraving Limited, Thetford, Norfolk, Great Britain. 1994:2-8.
85. Catlin DH. Androgen abuse by athletes. In: Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C, Kelly C, eds. International Androgen Workshop (2nd): Pharmacology, Biology, and Clinical Applications of Androgens: current status and future prospects. Wiley-Liss, Inc., New York, 1995:289-300.
86. Aguilera R, Becchi M, Casabianca H, Hatton CK, Catlin DH, Starcevic B, Pope HG. Improved method of detection of testosterone abuse by gas chromatography/ combustion/isotope ratio mass spectrometry analysis of urinary steroids. *J Mass Spectrometry* 1996;31:169-176.
87. Catlin DH, Cowan DA, de la Torre R, Donike M, Fraise D, Oftebro H, Hatton CK, Starcevic B, de la Torre X, Norli H, Geyer H, Walker CJ. Urinary testosterone (T) to epitestosterone (E) ratios by GC/MS. I. Initial comparison of uncorrected T/E in six international laboratories. *J Mass Spectrometry* 1996;31:397-402.
88. Catlin DH, Murray TH. Performance Enhancing Drugs, Fair Competition, and Olympic Sport. *JAMA* 1996;276:231-237.
89. Catlin DH, Murray TH. Response to: Performance Enhancing Drugs, Fair Competition, and Olympic Sport. *JAMA* 1996;276:1471. (Letter to Editor)
90. Catlin DH, Hatton CK, Starcevic S. Issues in detecting xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. *Clin Chem* 1997;43:1280-1288.

PUBLICATIONS (Continued):

91. Olesen H, Cowan D, Klempel K, Bruunshuus I, Hill G. International Federation of Clinical Chemistry: Committee on Laboratory Assessment on Drugs of Abuse (DH Catlin, Chairman) and Committee on Quantities and Units, and International Union of Pure and Applied Chemistry. Properties and units in drugs of abuse. (Committee work product, Chairperson of committee, 1997)
92. Catlin, DH. Effects and complications of anabolic androgenic steroids. In: Karch, SB, ed. Handbook on Drug Abuse. CRC Press LLC, 1998:653-662..
93. Starcevic B, Catlin DH, Di Stefano E, Luo W. Quantitative determination of anabolic steroid conjugates in human urine by LC-MS-MS. Proceedings of the 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, Florida, May 31-June 4, 1998. (Extended abstract).
94. Starcevic B, Di Stefano E, Catlin DH,, Luo W, Tabuchi R, Ghoborah H. Assay of Oxandrolone in Plasma and Urine. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics, Palm Springs, California, June 1-5, 1997. (Extended abstract).
95. Vihil DV, Puffer JC, Catlin, DH, Johnson TW, Jung ME, Starcevic B. Thermoprotective effect of bromantan administered to rats before aerobic exercise. Am College of Sports Medicine, June, 1998. (Abstract)
96. Lee EK, Starcevic S, Catlin DH. Effects of dietary supplements, 19-norandrostenedione, androstenediol and androstenedione on the profile of urine steroids. Western Society of Clinical Investigation. Carmel, Ca. January, 1999. (Abstract)
97. Catlin DH. Androgen abuse in sport: International and national anti-androgen programs. In: Wang C, Swerdloff R, eds. Male Reproduction Function. Kluwer Academic Publishers, 1999.
98. Longman J. Getting the chemical edge. [Catlin DH, Graphic text/illustration] New York Times, December 26, 1998. p A1 and p B6-B7.
99. Aguilera R, Catlin DH, Becchi M, Phillips A, Wang C, Swerdloff RS, Pope HG, Hatton CK. Screening urine for exogenous testosterone by isotope ratio mass spectrometric analysis of one pregnanediol and two androstanediols. J Chromatog B 1999;727:95-105.
100. Catlin DH. Doping. International Olympic Committee; 1999:1-40.
101. Sheffield-Moore M, Ferrando AA, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DH, Wolfe RR. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. Endocrine Society, 1999 (Abstract)

PUBLICATIONS (Continued):

102. Wang C, Catlin DH, Ambler C, Berman N, Lucas G, Leung A, Lee P, Starcevic B, Schramm KM, Swerdloff RS. Dietary fat modulation of androgen metabolism in normal men. Endocrine Society, 1999 (Abstract)
103. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration increases serum testosterone concentrations in young men. Endocrine Society, 1999 (Abstract)
104. Strawford A, Barbieri T, Van Loan M, Park E, Catlin DH, Barton N, Neese R, Christiansen M, King J, Hellerstein M. Effects of resistance exercise combined with supraphysiologic androgen therapy, including an anabolic steroid, oxandrolone, on lean tissue accrual and muscle strength in eugonadal men with HIV-related weight loss. A randomized, placebo-controlled trial. *JAMA* 1999;281:1282-1290.
105. Moore MS, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, Wolfe RR, Ferrando AA. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. *J Clin Endocrinol Metab* 1999;84:2705-2711.
106. Shipley A. With drug tests, answers are few. [Catlin, DH. Graphics, photos, text] *Washington Post*. September 22, 1999 p D1, D6-7, and September 23, 1999 p D1, D10-11.
107. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration increases serum testosterone concentrations in young men. *JAMA* 2000;283:779-782.
108. Starcevic B, Di Stefano E, Catlin DH. LC/MS/MS screening for beta-blockers and beta-2 agonists in urine with automated sample preparation. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics, Anaheim, California, June, 2000. (Extended abstract)
109. Aguilera R, Chapman TE, Catlin DH. Fast screening method for the detection of exogenous anabolic steroids in urine by gas chromatography / combustion / isotope ratio mass spectrometry. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics, Anaheim, California, June, 2000. (Extended abstract 1535)
110. Catlin DH. Use and abuse of anabolic steroids. In DeGroot LJ, ed. *Endocrinology*, 4th ed. Orlando, Florida: W.B. Saunders Co. 2000:2243-2256.
111. Aguilera R, Chapman TE, Catlin DH. A rapid screening assay for measuring urinary androsterone and etiocholanolone $\delta^{13}(^0/_{00})$ values by gas chromatography/combustion /isotope ratio mass spectrometry. *Rapid Comm Mass Spec* 2000;14:2294-2299.

PUBLICATIONS (Continued):

112. Catlin DH, Leder BZ, Ahrens B, Starcevic B, Hatton CK, Green GA, Finkelstein JS. Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite. *JAMA* 2000;284:2618-2621.
113. Aguilera R, Chapman TE, Catlin DH. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. *Clin Chem* 2001;47:292-300.
114. Catlin, DH, Jackson R.. Doping Control. In: Jackson R, ed. IOC Sport Medicine Manual, 2000 Hurford Enterprises Ltd., Calgary, Canada. 2000:332-343.
115. Catlin, DH. Hatch does not have all the facts. *Salt Lake City Tribune*, December 29, 2000. (Editorial)
116. Leder BZ, Catlin DH, Longcope C, Ahrens B, Schoenfeld DA, Finkelstein JS. Metabolism of orally administered androstenedione in young men. *J Clin Endocrinol Metab* 2001; 86:3654-3658.
117. Breidbach A, Catlin DH. RSR13, A potential athletic performance enhancement agent: detection in urine by GC-MS. *Rapid Commun Mass Spectrom* 2001;15:2379-82.
118. Green GA, Starcevic B, and Catlin DH. Analysis of over-the-counter steroid supplements. *Clin J Sports Med* 2001;11:254-259.
119. Catlin, DH, Leder BZ, Ahrens BD, Hatton CK, Finkelstein JS. Epitestosterone: precursor, metabolites, and effect of androstenedione administration. *Steroids* 2002;67:559-564.
120. Aguilera R, Hatton CK, Catlin DH. Detection of doping with epitestosterone by isotope ratio mass spectrometry. *Clin Chem* 2002;48:629-636.
121. Catlin DH, Ahrens BD, Kucherova Y. Detection of norbolethone, an anabolic steroid never marketed, in athletes' urines. *Rapid Commun Mass Spectrom* 2002;16:1273-1275.
122. Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. *Clin Chem* 2002;48:2057-2059.
123. Leder BZ, Leblanc KM, Longcope C, Lee H, Catlin DH, Finkelstein JS. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. *J Clin Endocrinol Metab* 2002;87:5449-5454.
124. Starcevic B, DiStefano E, Wang C, Catlin DH. Liquid chromatographic-tandem mass spectrometric assay for human testosterone and deuterated testosterone. *Journal of Chromatography B* 2003;792:197-204.

PUBLICATIONS (Continued):

125. Breidbach A, Catlin DH, Green GA, Tregub I, Truong H, Gorzek J. Detection of rHuEPO in urine by isoelectric focusing. *Clin Chem* 2003;49:901-907.
126. Catlin DH, Hatton CK, Lasne F. Abuse of Recombinant Erythropoietins by Athletes. In: Molineux G, Foote MA, Elliott S, eds. *Erythropoietins and erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology*. Birkhäuser Verlag, 2003:205-227.
127. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: Comparison of current laboratory methods *versus* liquid chromatography-tandem mass spectrometry. *J Clin Endocrin Metab* 2004;89:534-543.
128. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, Lucas G, Hull L, Swerdloff RS. Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: Influence of ethnicity and age. *J Clin Endocrin Metab* 2004;89:2936-2941.
129. Jasuja R, Catlin DH, Miller A, Chang Y-C, Singh R, Starcevic B, Artaza J, Ramaraj P, Bhasin S. Tetrahydrogestrinone (THG) binds to androgen receptor (AR) and activates AR-mediated signaling pathway. Endocrine Society, 2004 (Abstract)
130. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. *Rapid Commun Mass Spectrom* 2004;18:1245-1249.
131. Sekera MH, Ahrens BD, Chang Y-C, Starcevic B, Georgakopoulos C, Catlin DH. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. *Rapid Commun Mass Spectrom* 2005;19:781-784.
132. Wang C, Catlin DH, Starcevic B, Heber D, Ambler C, Berman N, Lucas G, Leung A, Schramm, Lee PWN, Hull L, Swerdloff RS. Low fat high fiber diet decreased serum and urine androgens in men. *J Clin Endocrin Metab* 2005;90:3550-3559.
133. Chang Y-C, Starcevic B, Ahrens BD, Strouse JM, Catlin DH. Identification of a urinary metabolite of the designer steroid tetrahydrogestrinone. 53rd Amer Soc Mass Spec Conference, San Antonio, 2005 (lognumber 1980).
134. Jasuja R, Catlin DH, Miller A, Chang Y-C, Herbst KL, Starcevic B, Artaza JN, Singh R, Datta D, Sarkissian A, Chandsawangbhuwana C, Baker M, Bhasin S. Tetrahydro-gestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. *Endocrinology*. 2005;146:4472-4478.

PUBLICATIONS (Continued):

135. Catlin DH, Chang YC, Starcevic B, Hatton CK. LC-MS measurement of anabolic steroids. In *Chromatographic methods in clinical chemistry and toxicology*. Eds Bertholf RL and Winecker RE. Chichester, U.K.: John Wiley & Sons. (In press, 2006)
136. Catlin DH, Starcevic B, Chang YC, Hatton CK. Sports doping analysis using LC-MS. In:
Gross ML and Caprioli RM. Eds. Vol 8, *Encyclopedia of Mass Spectrometry*. Oxford, UK: Elsevier.2006;879-887.
137. Catlin DH. Use and abuse of anabolic steroids. In: DeGroot LJ, and Jameson JL eds. *Endocrinology*, 5th ed. Orlando, Florida: W.B. Saunders Co. 2006:2243-2256.
138. Catlin DH, Green G, Sekera MH, Scott P, Starcevic B. False positive EPO test concerns unfounded. *Blood* 2006;108:1778. (Letter to the editor)
139. Jeong, J-Y, Changmin C, Davis KL, Breidbach A, Catlin DH, Sytkowski, AJ. Erythropoietin Fusion Proteins Comprised of Identical Head-to-Tail Repeats with Enhanced Biological Activity. (Abstract, 2006)
140. Catlin DH, Green GG, Hatton CK. Drugs in Sport. In *The Olympic book of Medicine in Sport*. Ed. Schwellnus M. Blackwell Publishing Ltd. (In press, 2008)
141. Green G, Aguilera R, Ahrens B, Starcevic B, Kurtzman F, Su J, Catlin DH. The Influence of Diet on Isotope Ratio Mass Spectrometry Values. *Clin J Sports Med*. (in Press 2009).

NEWSPAPER ARTICLES BASED ON ANALYTICAL WORK OF CATLIN, DH AND OTHERS AT THE UCLA OLYMPIC ANALYTICAL LABORATORY

1. Shipley A. Chemists Stay a Step Ahead of Drug Testers. *Washington Post*. October 18, 2005;p E01
2. Shipley A. Chemist's New Product Contains Hidden Substance. *Washington Post*. May 8, 2006, p E01
3. ESPN Sports. Results of supplement analyses.

FILM

1. Doping: The battle for the soul of Sport. Hilton Cordell Productions for Discovery Times Channel in Association with the Canadian Broadcasting corporation and the Australian Broadcasting Corporation, 2004. (<http://www.hiltoncordell.com/>)

MEDIA ARTICLES FOCUSED ON CATLIN (Partial listing since 6/2005)

Outside Magazine Feature July 2005 Brian Alexander
Topic: Profile of Catlin's Volunteer Program

Reuters Jul 16, 2005 Gene Cherry
Topic: Doping-More scandals possible after BALCO, key scientist says

Associated Press Feature January 25, 2007 Paul Elias and David Kravets
Topic: Steroid scientist dogs athletes, is key BALCO witness

Los Angeles Magazine June 2007
Topic: Profile of Catlin

USA Today Jill Lieber June 2007
Topic: Profile of Catlin

HBO Costas Now July 2007 Bob Costas Brief appearance
Topics: Drugs in baseball, Bonds, testing, Selig, Schilling, Patrick Arnold

New York Times 29 July 2007 Author: Juliet Macur
Topic: why do athletes dope?

Science Journal:Analytical Chemistry August 2007 Raj Mukhopadhyay
Topic: Analytical Chemistry plays a key role in Unmasking Athletes who take Performance-Enhancing Drugs (Catlin and others).

Kansas City Star July 31, 2007 Interviewer: Sam Mellinger
Topic: Bonds, Baseball, Selig, and our grant for hGH

University of Rochester Review Fall 2007
Topic: in depth personal interview on Catlin career future plans and aspirations.

National Public Radio Morning Edition December 19, 2007 Tom Goldman
Tom Goldman Listen <http://www.npr.org/templates/story/story.php?storyId=17390477>
Topic: Mitchell Report

Washington Post 12/20/2007 Amy Shipley
Topic WADA and hGH

Radio24-IIsole24Ore, An italian national news radio broadcast. Milano, Italy
January 3, 2008 Dario Ricci
Topic: Update on Drugs and Sport

MEDIA ARTICLES FOCUSED ON CATLIN (Partial listing since 6/2005)

XM Radio January 18, 2008 Brent Gambill
Topic: The latest on Anti-Doping Research

National Public Radio, New York February 15, 2008 Leonard Lopate
Topic: human Growth Hormone and other drugs